BPC 157 for Foot Pain Houston Podiatrist Explains FDA Peptide Category 2 Removal & Public Meeting July 23rd Mansi Hukmani posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA mulls compounding for peptides previously flagged over safety risks BioSpace